Wegovy Pill vs Wegovy Injection: Comparing Oral and Injectable Semaglutide

The Wegovy pill is once-daily oral semaglutide at a 25 mg maintenance dose, approved by the FDA for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, and also for reducing the risk of major adverse cardiovascular events. It is the first oral GLP-1 receptor agonist approved for weight loss.

Getting a peptide to work as a tablet is genuinely difficult, which is why this took so long. Semaglutide is a large molecule that stomach acid and digestive enzymes would normally destroy, and even intact it does not cross the gut wall easily. The tablet is formulated with an absorption enhancer that briefly raises local pH and helps a small fraction of the dose cross the stomach lining before it is broken down.

"A small fraction" is not an exaggeration. Only around 1% of the oral dose reaches the bloodstream, which is why the tablet contains 25 mg to achieve exposure comparable to a 2.4 mg weekly injection. It also explains why the administration rules are unusually strict: anything else in your stomach interferes with that narrow window of absorption.

It is worth separating the Wegovy pill from Rybelsus, which confuses a lot of people. Rybelsus is also oral semaglutide, but it is approved for type 2 diabetes at 3, 7, and 14 mg. The doses are far lower and it is not approved for weight management. Same molecule, different product, different indication.

The two forms land in the same territory, and neither has a decisive advantage on efficacy alone.

In OASIS 4, oral semaglutide 25 mg produced 16.6% mean weight loss among participants who adhered to treatment, and roughly one in three lost 20% or more of their body weight. In STEP 1 (NEJM 2021), injectable semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks, with about a third of participants losing 20% or more.

Before reading too much into the gap, note the important caveat. The oral figure describes results when treatment was adhered to, an analysis approach that excludes the effect of people stopping or missing doses. Trials also differ in length, population, and design, so cross-trial comparison is suggestive rather than definitive. The fair conclusion is that they are broadly equivalent.

For context, tirzepatide, a dual GIP and GLP-1 agonist, produced 20.9% mean weight loss at the 15 mg dose in SURMOUNT-1 (NEJM 2022). That remains the highest figure among widely available options, and it is the main reason some women choose an injectable in a different class entirely. [Switching between the two is covered here](/blog/switching-from-ozempic-to-mounjaro-when-and-how).

The cardiovascular data also carry across. The SELECT trial (NEJM 2023) found a 20% reduction in major adverse cardiovascular events with injectable semaglutide in over 17,000 adults with obesity and established cardiovascular disease, and the oral formulation carries an approval for cardiovascular risk reduction as well.

The administration rules are the single biggest practical difference, and they are not optional suggestions. Absorption depends on them.

Take it first thing in the morning, on an empty stomach, before eating or drinking anything else.

Use no more than 4 ounces of plain water, which is about half a standard glass. More water dilutes the absorption enhancer and reduces how much drug gets through. Not less than that either, since the tablet needs to reach the stomach.

Swallow it whole. Do not split, crush, or chew the tablet. The 25 mg tablet in particular must not be broken to create a smaller dose.

Wait at least 30 minutes before eating, drinking anything else, or taking any other oral medication. This is the part women find hardest, especially if you take a thyroid medication that has its own fasting requirement, which is worth raising with your prescriber.

One tablet a day, no more, and if you miss a dose, skip it and resume the next morning.

The dose ladder runs 1.5 mg for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, and 25 mg as the maintenance dose from day 91. If a step is not tolerated, escalation can be delayed rather than pushed through, the same principle that applies to injectable titration. [More on when to hold a dose](/blog/glp1-dose-escalation-when-to-increase-and-when-to-hold).

The side effect profile is largely the same, because it is the same drug acting on the same receptors. Nausea, vomiting, and diarrhoea are the most common adverse reactions with both forms, and constipation, fatigue, burping, and abdominal discomfort are all frequently reported.

There are a few differences in how side effects are distributed across time rather than in what they are.

Daily dosing spreads exposure more evenly. A weekly injection produces a peak in drug concentration in the days after the shot, which is why many women describe a predictable rhythm of a rough day or two followed by an easier stretch. Daily dosing flattens that curve. Whether this makes nausea better or simply more constant appears to vary between individuals.

The fasting requirement can amplify morning nausea. Taking a medication that slows gastric emptying on a completely empty stomach, then waiting half an hour before eating, is not comfortable for everyone.

Injection site reactions disappear entirely with the pill, which matters for a minority of women who get persistent redness or itching.

The serious warnings are identical across all semaglutide products, including the boxed warning about thyroid C-cell tumours seen in rodents, contraindications in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, and cautions around pancreatitis, gallbladder disease, and diabetic retinopathy. Neither form is safer than the other in this respect.

One thing that does change is the rhythm of eating. Women on weekly injections often plan around a specific day, as [this guide to eating on injection day](/blog/what-to-eat-on-glp1-injection-day-meal-guide) describes. On a daily tablet, that pattern flattens out.

Choose based on the routine you will actually keep, because adherence is where the real difference in outcomes lives.

The pill suits you if you have a genuine needle phobia, you already have a stable morning routine and get up at a consistent time, you travel frequently and would rather not manage refrigeration and sharps disposal, or you find the psychological weight of a weekly injection a barrier to starting at all. Some women also prefer the privacy of a tablet.

The injection suits you if you are not a morning person, your schedule is irregular, you eat or drink coffee immediately on waking, or you take other morning medications with their own timing rules. One weekly decision is easier to protect than 365 small ones. It also suits you if you find daily medication a constant reminder of a condition you would rather not think about every morning.

The question to ask yourself honestly: could you, for the next two years, wake up and wait 30 minutes before your first coffee, every single day? For some women that is trivially easy. For others it is the thing that quietly ends the treatment by month four.

And remember there is no permanence to the choice. Switching between formulations of the same drug is straightforward under clinical guidance, and plenty of women will start on one and move to the other.

If you are also weighing up the branded products, [the difference between Ozempic and Wegovy](/blog/ozempic-vs-wegovy-same-drug-different-approval) is worth understanding, since they are also the same drug with different approvals.

Cost is moving quickly in this category, and the oral launch has pushed it further.

The Wegovy pill launched with a savings offer around $149 per month for the starting dose through pharmacies and select telehealth providers, which is substantially below historical list prices for branded GLP-1s. Pricing at maintenance doses, and what you actually pay, will depend on your insurance, your pharmacy, and whether you use a manufacturer savings programme.

The broader picture for weight management coverage remains uneven. Many commercial plans still exclude obesity medications outright or require documented prior attempts at lifestyle intervention. Coverage is generally easier to obtain when there is a qualifying comorbidity such as type 2 diabetes, sleep apnoea, or established cardiovascular disease, and the cardiovascular indication has made some plans more willing.

A few practical notes:

• •Manufacturer savings cards typically require commercial insurance and exclude anyone on Medicare or Medicaid.
• •Prior authorisation is common. Your prescriber's documentation of BMI, comorbidities, and prior attempts does most of the work.
• •FSA and HSA funds can generally be used for prescribed weight management medication. [What is eligible in 2026](/blog/fsa-hsa-for-glp1-what-is-eligible-2026) covers the details.
• •Oral formulations may be easier to distribute than injectables, which has historically been a source of supply disruption.

Do not assume price alone should decide this. A cheaper medication you abandon in month three because the routine does not fit your life costs more than the one you stay on.

Come with specific questions rather than a general request, and the appointment will go better.

On suitability: Do I have any contraindication to semaglutide in either form, particularly thyroid history, pancreatitis, or gallbladder disease? Given my medical history, is a GLP-1 or a dual agonist like tirzepatide the better starting point?

On the routine: I take other morning medications, including any with fasting requirements. How should we sequence them around a 30-minute wait? Realistically, how strictly does the empty-stomach rule need to be followed?

On monitoring: What are we tracking, and how often? This should include weight, blood pressure, and relevant bloodwork rather than weight alone.

On the plan: What happens if I do not tolerate a titration step? At what point would we consider this not working? Is the intention long-term treatment, and what does stopping look like?

On coverage: Which form is covered by my plan, and what documentation do you need from me for prior authorisation?

One larger point worth holding onto. Whichever form you choose, the outcome depends heavily on things the prescription does not cover: eating enough protein to protect muscle, resistance training, sleep, and hydration. The medication makes those things possible by quieting hunger. It does not do them for you. [How GLP-1s work mechanistically](/blog/how-glp1-medications-work-mechanism-explained) is a useful foundation if you want to understand what the drug is and is not doing.